Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKAZAR: NVL-655 vs alectinib in first-line ALK-positive advanced NSCLC
jRCT2071250073Phase 3Not yet recruiting
- Sponsor
- Nuvalent
- Start
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of neladalkib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Nuvalent. Primary endpoint: Progression-free survival (PFS) by BICR. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
neladalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2071250073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250073.